| Original language | English |
|---|---|
| Pages (from-to) | 1391-1395 |
| Number of pages | 5 |
| Journal | Clinical and Experimental Allergy |
| Volume | 51 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2021 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Clinical and Experimental Allergy, Vol. 51, No. 10, 10.2021, p. 1391-1395.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Effectiveness of lanadelumab for preventing hereditary angioedema attacks
T2 - Subgroup analyses from the HELP study
AU - HELP Study Investigators
AU - Johnston, Douglas T.
AU - Busse, Paula J.
AU - Riedl, Marc A.
AU - Maurer, Marcus
AU - Anderson, John
AU - Nurse, Christina
AU - Inhaber, Neil
AU - Yu, Ming
AU - Banerji, Aleena
AU - Hébert, J.
AU - Ritchie, B.
AU - Sussman, G.
AU - Yang, W. H.
AU - Escuriola Ettingshausen, C.
AU - Magerl, M.
AU - Martinez-Saguer, I.
AU - Maurer, M.
AU - Staubach, P.
AU - Zimmer, S.
AU - Cicardi, M.
AU - Perego, F.
AU - Wu, M. A.
AU - Zanichelli, A.
AU - Al-Ghazawi, A.
AU - Shennak, M.
AU - Zaragoza-Urdaz, R. H.
AU - Ghurye, R.
AU - Longhurst, H. J.
AU - Zinser, E.
AU - Anderson, J.
AU - Banerji, A.
AU - Baptist, A. P.
AU - Bernstein, J. A.
AU - Boggs, P. B.
AU - Christiansen, S.
AU - Craig, T.
AU - Davis-Lorton, M.
AU - Gierer, S.
AU - Gower, R. G.
AU - Harris, D.
AU - Hong, D. I.
AU - Jacobs, J.
AU - Johnston, D. T.
AU - Levitch, E. S.
AU - Li, H. H.
AU - Lockey, R. F.
AU - Lugar, P.
AU - Lumry, W. R.
AU - Manning, M. E.
AU - McNeil, D. L.
AU - Melamed, I.
AU - Mostofi, T.
AU - Nickel, T.
AU - Otto, W. R.
AU - Petrov, A. A.
AU - Poarch, K.
AU - Radojicic, C.
AU - Rehman, S. M.
AU - Riedl, M. A.
AU - Schwartz, L. B.
AU - Shapiro, R.
AU - Sher, E.
AU - Smith, A. M.
AU - Smith, T. D.
AU - Soteres, D.
AU - Tachdjian, R.
AU - Wedner, H. J.
AU - Weinstein, M. E.
AU - Zafra, H.
AU - Zuraw, B. L.
N1 - Funding Information: The HELP study was sponsored by Shire Human Genetic Therapies, Inc., a Takeda company, Lexington, MA, USA. Under direction of the authors, Shirley Teng, PhD, CMPP, employee of Excel Medical Affairs, provided writing assistance for this manuscript. Editorial assistance in formatting, proofreading, copy-editing and fact-checking also was provided by Excel Medical Affairs. Shire Human Genetic Therapies, Inc., a Takeda company, provided funding to Excel Medical Affairs for support in writing and editing this manuscript. We thank all patients, investigators and their study staff. We would like to acknowledge the late Dr Marco Cicardi, who was an Investigator for the HELP study and provided valuable insight into the interpretation of the study results. Funding Information: DTJ has received consulting/speaker fees from CSL Behring, Pharming and Shire (a Takeda company); and consulting fees from BioCryst and Regenxbio. PJB reports grants from Shire (a Takeda company); a lecture honorarium from CVS Health; and consulting fees from BioCryst, CSL Behring, Pearl Therapeutics, Pharming and Shire (a Takeda company). MAR has received research grants from BioCryst, CSL Behring, Pharming and Shire (a Takeda company); consulting fees from Adverum, Attune, BioCryst, CSL Behring, KalVista, Pharming, Pharvaris and Shire (a Takeda company); speaker honoraria from CSL Behring, Pharming and Shire; and is a medical advisory board member of the US Hereditary Angioedema Association. MM has received research grant support and/or speaker/consultancy fees from Adverum, Attune, BioCryst, CSL Behring, KalVista, Pharming, Pharvaris and Shire (a Takeda company). JA is a speaker bureau member for CSL Behring, Pharming, Biocryst and Shire (a Takeda company); has received consultancy fees from CSL Behring, Pharming and Shire (a Takeda company); and is a clinical trial investigator for Pharming, KalVista, BioCryst, CSL Behring and Shire (a Takeda company). CN, NI and MY are full‐time employees of Takeda Pharmaceutical Company Limited and hold stock/stock options in Takeda. AB has received institutional research/study support from BioCryst and Shire (a Takeda company) and/or honoraria for consulting from BioCryst, CSL Behring, KalVista, Pharming, Pharvaris and Shire (a Takeda company). Funding Information: The HELP study was sponsored by Shire Human Genetic Therapies, Inc., a Takeda company, Lexington, MA, USA. Under direction of the authors, Shirley Teng, PhD, CMPP, employee of Excel Medical Affairs, provided writing assistance for this manuscript. Editorial assistance in formatting, proofreading, copy‐editing and fact‐checking also was provided by Excel Medical Affairs. Shire Human Genetic Therapies, Inc., a Takeda company, provided funding to Excel Medical Affairs for support in writing and editing this manuscript.
PY - 2021/10
Y1 - 2021/10
UR - https://www.scopus.com/pages/publications/85113183008
U2 - 10.1111/cea.13974
DO - 10.1111/cea.13974
M3 - Letter
C2 - 34166549
AN - SCOPUS:85113183008
SN - 0954-7894
VL - 51
SP - 1391
EP - 1395
JO - Clinical and Experimental Allergy
JF - Clinical and Experimental Allergy
IS - 10
ER -